This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignees: Centre National De La Recherche Scientifique, Ecole Normale Superieure De Lyon, National Institute of Health and Medical Research. Active years: 2023.
Company Filing History:
1 out of 5,383 
1 out of 44 
1 out of 1,853 
Years Active: 2023
Title: The Innovations of Ruben Bender
Introduction
Ruben Bender is an accomplished inventor based in Frankfurt-am-Main, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of retroviral vectors for therapeutic applications. His innovative work has the potential to impact gene therapy and immune modulation.
Latest Patents
Ruben Bender holds a patent for a pseudotyped retrovirus-like particle or retroviral vector that incorporates engineered envelope glycoproteins derived from the Paramyxoviridae family. This invention is designed to selectively modulate the activity of specific immune cells, making it particularly useful for gene therapy, immune therapy, and vaccination. The patent is titled "Nipah virus envelope glycoprotein pseudotyped lentivirus" and represents a significant advancement in targeted therapeutic strategies.
Career Highlights
Throughout his career, Ruben has worked with prestigious institutions such as École Normale Supérieure de Lyon and the Centre National de la Recherche Scientifique. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Ruben has collaborated with notable colleagues, including Caroline Costa Fejoz and Els Verhoeyen. These partnerships have enriched his research and expanded the impact of his innovations.
Conclusion
Ruben Bender's work exemplifies the intersection of innovation and biotechnology. His contributions to the development of targeted therapeutic vectors highlight the potential for advancements in gene therapy and immune modulation.